Tolerance and Safety of a Duodenal Probe Monitoring the Microcirculation

Not Applicable

Completed

• Conditions: Multiple Organ Dysfunction Syndrome

• Registration Number: NCT02246036
• Lead Sponsor: Advanced Perfusion Diagnostics

Brief Summary

For Intensive Care Units (ICU) patients, Multiple Organ Dysfunction Syndrome (MODS) is a very common complication yielding high morbidity and mortality. Inadequate regional perfusion of certain organs (gut, kidney, liver, etc) often caused by shock is the main cause of MODS. Current practice uses cardiac output data and blood pressure to manage shock but there are still lacks of information about the regional perfusion. This leads to late MODS diagnostics preventing the implementation of adequate treatment.

Gut perfusion monitoring seems to be a good target to assess the microcirculation but, nowadays, no practical methods or devices are available to measure the gut perfusion, and the current monitoring methods are not specific (CO, BP, OPS-SDF, PCO2, etc).

"MC Monitor" trial is a prospective, multi-center pilot study, enrolling 10 patients.

The probe will be used by intensivists on ICU patients with a risk of shock and requiring mechanical ventilation.

The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement). This procedure will be used to assess the status of the gut mucosa prior to the placement of the APD probe.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-09-18
• Study First Submitted QC: 2014-09-18
• Study First Posted: 2014-09-22
• Study Start: 2014-12
• Primary Completion: 2016-09
• Study Completion: 2016-09
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-12
• Last Update Posted: 2016-10-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• 18 years of age or more,
• Male or female,
• ICU patient, on vasoactive amines, under mechanical ventilation,
• Stable hemodynamic status,
• Life expectancy expected to exceed 72 hours,
• Length of ICU stay greater than 5 days,
• Willing to participate and signed informed consent,
• Affiliation to the French social security system.

Exclusion Criteria

• Pregnant or lactating woman,
• Ongoing enteral nutrition,
• Risk of gastrointestinal ischemia,
• History of pharyngeal surgery surgery, esophageal surgery, radiotherapy of mediastinal area,
• Known ear-nose-throat malignant disease,
• Unexplored dysphagia,
• Known recent gastrointestinal suture,
• Esophageal varices,
• Abdominal pain,
• Unstable cervical fracture,
• Moribund patient,
• Active participation in another investigational protocol within the past 30 days,
• Subject legally protected, under legal guardianship, deprived of his/her liberty by judicial or administrative decision.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Absence of duodenal lesions	24 hours	Duodenal lesions are defined as visible alterations of the duodenum.

Secondary Outcome Measures

Name	Time	Method
Signal-to-noise ratio of the APD probe	24 hours	The signal is a reflect of the pulsatile flow in the duodenum. This assertion is evaluated thanks to a signal-to-noise ratio of the cardiac frequency in the PPG on other non-filtered signal componants.

Trial Locations

Locations (3)

CHU Estaing - Service réanimation adultes; 🇫🇷 Clermont-ferrand, France

Centre Hospitalier Lyon-Sud; 🇫🇷 Lyon, France

GHU Caremeau - Unité REA; 🇫🇷 Nimes, France